Becton, Dickinson and Company (BDX) To Go Ex-Dividend on December 7th

Becton, Dickinson and Company (NYSE:BDX) declared a quarterly dividend on Monday, November 20th, RTT News reports. Stockholders of record on Friday, December 8th will be paid a dividend of 0.75 per share by the medical instruments supplier on Friday, December 29th. This represents a $3.00 annualized dividend and a dividend yield of 1.33%. The ex-dividend date of this dividend is Thursday, December 7th. This is a boost from Becton, Dickinson and’s previous quarterly dividend of $0.73.

Becton, Dickinson and has increased its dividend payment by an average of 10.1% per year over the last three years and has raised its dividend every year for the last 45 years. Becton, Dickinson and has a payout ratio of 28.2% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Becton, Dickinson and to earn $11.79 per share next year, which means the company should continue to be able to cover its $3.00 annual dividend with an expected future payout ratio of 25.4%.

Becton, Dickinson and (NYSE BDX) opened at $226.33 on Friday. Becton, Dickinson and has a 12-month low of $161.29 and a 12-month high of $229.68. The stock has a market capitalization of $51,170.00, a P/E ratio of 24.05, a P/E/G ratio of 1.79 and a beta of 1.04. The company has a debt-to-equity ratio of 1.44, a quick ratio of 5.03 and a current ratio of 5.58.

Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.37 by $0.03. Becton, Dickinson and had a return on equity of 20.56% and a net margin of 8.52%. The business had revenue of $3.17 billion during the quarter, compared to analyst estimates of $3.14 billion. During the same quarter in the previous year, the firm posted $2.12 EPS. The business’s revenue for the quarter was down 2.0% compared to the same quarter last year. equities analysts forecast that Becton, Dickinson and will post 10.63 earnings per share for the current fiscal year.

In other Becton, Dickinson and news, insider Gary M. Cohen sold 15,512 shares of the business’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the completion of the transaction, the insider now owns 95,781 shares in the company, valued at approximately $19,517,294.37. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Stephen Sichak sold 11,787 shares of the business’s stock in a transaction on Friday, September 8th. The stock was sold at an average price of $200.46, for a total value of $2,362,822.02. Following the transaction, the insider now owns 14,038 shares of the company’s stock, valued at approximately $2,814,057.48. The disclosure for this sale can be found here. Insiders own 1.40% of the company’s stock.

A number of research analysts recently issued reports on the company. Stifel Nicolaus restated a “buy” rating and set a $245.00 price objective on shares of Becton, Dickinson and in a research report on Friday, November 3rd. Morgan Stanley boosted their price objective on Becton, Dickinson and from $205.00 to $245.00 and gave the company an “equal weight” rating in a research report on Friday, November 3rd. Royal Bank Of Canada restated a “sector perform” rating and set a $230.00 price objective (up previously from $210.00) on shares of Becton, Dickinson and in a research report on Friday, November 3rd. Zacks Investment Research upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $234.00 price objective for the company in a research report on Tuesday, October 31st. Finally, Wells Fargo & Company restated a “positive” rating and set a $235.00 price objective (up previously from $225.00) on shares of Becton, Dickinson and in a research report on Tuesday, October 24th. They noted that the move was a valuation call. Four analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $217.08.

COPYRIGHT VIOLATION WARNING: “Becton, Dickinson and Company (BDX) To Go Ex-Dividend on December 7th” was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another website, it was stolen and reposted in violation of U.S. and international copyright and trademark legislation. The original version of this piece can be viewed at https://sportsperspectives.com/2017/12/02/becton-dickinson-and-company-bdx-to-go-ex-dividend-on-december-7th.html.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Dividend History for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply